Andrew R. Boll
2019
In 2019, Andrew R. Boll earned a total compensation of $1M as Chief Financial Officer at Imprimis Pharmaceuticals, a 90% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $178,680 |
|---|---|
| Option Awards | $185,370 |
| Salary | $348,063 |
| Stock Awards | $324,063 |
| Other | $13,042 |
| Total | $1,049,545 |
Boll received $348.1K in salary, accounting for 33% of the total pay in 2019.
Boll also received $178.7K in non-equity incentive plan, $185.4K in option awards, $324.1K in stock awards and $13K in other compensation.
Rankings
In 2019, Andrew R. Boll's compensation ranked 9,072nd out of 13,971 executives tracked by ExecPay. In other words, Boll earned more than 35.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,072 out of 13,971 | 35th |
Division Manufacturing | 3,639 out of 5,698 | 36th |
Major group Chemicals And Allied Products | 1,375 out of 2,197 | 37th |
Industry group Drugs | 1,172 out of 1,883 | 38th |
Industry Pharmaceutical Preparations | 867 out of 1,395 | 38th |
Source: SEC filing on April 24, 2020.
Boll's colleagues
We found two more compensation records of executives who worked with Andrew R. Boll at Imprimis Pharmaceuticals in 2019.
News
Imprimis Pharmaceuticals CEO Mark Baum's 2022 pay falls 84% to $1.2M
April 28, 2023
Imprimis Pharmaceuticals CEO Mark Baum's 2021 pay jumps 195% to $7.3M
April 26, 2022
Imprimis Pharmaceuticals CEO Mark Baum's 2020 pay jumps 80% to $2.5M
April 23, 2021
Imprimis Pharmaceuticals CEO Mark Baum's 2019 pay jumps 30% to $1.4M
April 24, 2020
Imprimis Pharmaceuticals CEO Mark Baum's 2018 pay rises 16% to $1.1M
April 25, 2019